Cizzle Biotechnology Holdings Plc
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CIZ.L research report →
Companywww.cizzlebiotechnology.com
Cizzle Biotechnology Holdings Plc engages in development of an immunoassay test for the CIZ1B biomarker for the early detection of lung cancer. The company was formerly known as Cizzle Biotechnology Limited and changed its name to Cizzle Biotechnology Holdings Plc in May 2021. Cizzle Biotechnology Holdings Plc is headquartered in London, the United Kingdom.
- CEO
- Allan John Syms
- IPO
- 2021
- Employees
- 4
- HQ
- London, GB
Price Chart
Valuation
- Market Cap
- $12.54M
- P/E
- -36.16
- P/S
- 0.00
- P/B
- -34.39
- EV/EBITDA
- -33.48
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 104.99%
- ROIC
- 210.81%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-691,000 · -31802.12%
- EPS
- $-0.00 · 69.64%
- Op Income
- $-753,000
- FCF YoY
- -39.11%
Performance & Tape
- 52W High
- $3.90
- 52W Low
- $1.20
- 50D MA
- $2.40
- 200D MA
- $1.75
- Beta
- 0.07
- Avg Volume
- 1.66M
Get TickerSpark's AI analysis on CIZ.L
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our CIZ.L Coverage
We haven't published any research on CIZ.L yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CIZ.L Report →